Phase 1 × NIH × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × Clear all Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Phase 1 Recruiting
86 enrolled
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
Phase 1 Suspended
30 enrolled
Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma
Phase 1 Recruiting
20 enrolled
Veliparib and Temozolomide in Treating Patients With Acute Leukemia
Phase 1 Completed
66 enrolled
Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome
Phase 1 Completed
6 enrolled 16 charts
Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
Phase 1 Withdrawn
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma
Phase 1 Completed
34 enrolled
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers
Phase 1 Completed
17 enrolled
Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine Therapy
Phase 1 Completed
89 enrolled
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
Phase 1 Completed
80 enrolled
UCN-01 and Prednisone in Treating Patients With Solid Tumors or Lymphoma
Phase 1 Completed
LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or Lymphoma
Phase 1 Completed
40 enrolled
Immunotoxin in Treating Patients With Leukemia or Lymphoma
Phase 1 Completed
Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma
Phase 1 Completed
24 enrolled
Flavopiridol in Treating Patients With Refractory Cancer
Phase 1 Completed
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors
Phase 1 Completed
30 enrolled
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
Phase 1 Completed
42 enrolled
Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
Phase 1 Terminated
36 enrolled
Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction
Phase 1 Completed
15 enrolled
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma
Phase 1 Completed
57 enrolled
FAU in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Completed
12 enrolled
Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer
Phase 1 Unknown
30 enrolled
3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Completed
30 enrolled
Carbendazim in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Unknown
AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Unknown
18 enrolled
Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma
Phase 1 Unknown
30 enrolled
VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas
Phase 1 Completed
VNP40101M in Treating Patients With Advanced or Metastatic Cancer
Phase 1 Completed
17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer
Phase 1 Terminated
74 enrolled
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
Phase 1 Completed
BCX-1777 in Treating Patients With Refractory Cancer
Phase 1 Completed
Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma
Phase 1 Completed
28 enrolled
PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma
Phase 1 Terminated
36 enrolled
Monoclonal Antibody Therapy in Treating Patients With Advanced or Recurrent Lymphoma
Phase 1 Completed
PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
Phase 1 Completed
55 enrolled
Combination Chemotherapy in Treating Patients With Advanced Cancer
Phase 1 Completed
25 enrolled
Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis
Phase 1 Completed
Decitabine in Treating Patients With Melanoma or Other Advanced Cancer
Phase 1 Completed
Topotecan and Radiation Therapy in Treating Patients With Solid Tumors or Lymphoma
Phase 1 Completed
5 enrolled
Perillyl Alcohol in Treating Patients With Refractory Cancer
Phase 1 Completed
25 enrolled
Penclomedine in Treating Patients With Solid Tumors or Lymphoma
Phase 1 Completed
30 enrolled
Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer
Phase 1 Completed
40 enrolled
BMS-247550 in Treating Patients With Advanced Cancers
Phase 1 Completed
54 enrolled
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
Phase 1 Completed
60 enrolled
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction
Phase 1 Completed
60 enrolled
Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma
Phase 1 Completed
3 enrolled
Phenylbutyrate in Treating Patients With Refractory Solid Tumors or Lymphoma
Phase 1 Completed
24 enrolled
Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer
Phase 1 Completed
40 enrolled
Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma
Phase 1 Terminated
15 enrolled
17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas
Phase 1 Completed
60 enrolled